

In the Specification:

Please correct the paragraph at Page 13, line 24 to line 29, as follows:

The amount of HPMCAS relative to the amount of drug present in the dispersions of the present invention can vary widely from a drug:polymer weight ratio of 1 to 0.2 to 1 to 100. However, in most cases it is preferred that the drug to polymer ratio is greater than 1 to 20 ~~1 to 0.4~~ and less than 1 to 0.4 ~~1 to 20~~. The minimum drug:polymer ratio that yields satisfactory results varies from drug to drug and is best determined in the *in vitro* dissolution tests described below.

REMARKS


The above amendment corrects a typographical error which occurs at page 13, line 27. Although Applicants made the amendment in parent Application No. 09/131,019, the same amendment was inadvertently omitted by oversight in this application. It is respectfully submitted that the amendment is directed to a matter of form not affecting the scope of the application.

Applicants have corrected a typographical error in the paragraph that occurs at page 13, line 24 to line 29. The amendment has been effected to the wording at page 13, line 27. Specifically, the phrase "greater than 1 to 0.4 and less than 1 to 20" has been changed to - "greater than 1 to 20 and less than 1 to 0.4" -. Support for the amendment is at page 17, lines 5-6. It is also noted that the drug-polymer dispersions found in Tables I, II, III, IV, V, VI, VII, VIII, X, XII, XIII, XIV, XV, and XVI are all within the aforementioned (as now amended) preferred range.

Clearly, the amendment is supported. Entry of the amendment is accordingly respectfully requested as directed to a matter of form not affecting the scope of the invention.

Respectfully submitted,

Date: NOVEMBER 24, 2003


James T. Jones
Attorney for Applicant
Reg. No. 30,561

Pfizer Inc
Patent Department
Eastern Point Road
Groton, CT 06340
(860) 441-4903